SCHEMBL5207598

SCHEMBL5207598

COc1cc[c]c(O)c1O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.46
KDM4E B2RXH2 3/20 0.46
MAPK1 P28482 3/20 0.46
HSD17B10 Q99714 3/20 0.46
CYP3A4 P08684 3/20 0.46
TP53 P04637 2/20 0.46
ALDH1A1 P00352 2/20 0.46
LMNA P02545 2/20 0.46
HPGD P15428 2/20 0.46
ALOX15 P16050 2/20 0.46
ALOX12 P18054 1/20 0.46
ERN1 O75460 2/20 0.38
TLR2 O60603 1/20 0.38
TLR1 Q15399 1/20 0.38
TLR6 Q9Y2C9 1/20 0.38
CA1 P00915 3/20 0.38
CA2 P00918 3/20 0.38
TSHR P16473 1/20 0.38
CA12 O43570 3/20 0.38
MAOB P27338 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4176958 0.80 KDM4E (0.45) MAPTKDM4EMAPK1HSD17B10CYP3A4
SCHEMBL2439645 0.80 MAPT (0.41) MAPTKDM4EMAPK1HSD17B10CYP3A4
SCHEMBL10336692 0.80 MAPT (0.45) MAPTKDM4EMAPK1HSD17B10CYP3A4
SCHEMBL10771504 0.80 TP53 (0.37) MAPTKDM4EMAPK1HSD17B10CYP3A4
SCHEMBL22833910 0.78 MAPT (0.43) MAPTKDM4EMAPK1HSD17B10CYP3A4
SCHEMBL5209906 0.78 TP53 (0.43) MAPTKDM4EMAPK1HSD17B10CYP3A4
SCHEMBL28567295 0.78 TP53 (0.35) MAPTKDM4EMAPK1HSD17B10CYP3A4
SCHEMBL28301283 0.78 EP300 (0.39) MAPTKDM4EMAPK1HSD17B10CYP3A4
SCHEMBL248531 0.73
SCHEMBL10447228 0.72 MAPT (0.38) MAPTKDM4EMAPK1HSD17B10CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303561-A1 PYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREOF AND USE THEREOF IN RESISTING MYCOBACTERIUM TUBERCULOSIS INFECTION INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2023-09-28 US claimed
EP-4180429-A1 PYRIMIDINONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF AGAINST MYCOBACTERIUM TUBERCULOSIS INFECTION Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences (CN) 2023-05-17 EP claimed
CN-114081890-A Application of pyrimidone derivatives in resisting mycobacterium tuberculosis infection 中国医学科学院医药生物技术研究所 2022-02-25 CN claimed
CN-111925368-B Pyrimidone derivatives, preparation method thereof and application thereof in resisting mycobacterium tuberculosis infection 中国医学科学院医药生物技术研究所 2021-11-05 CN claimed
CN-111925368-A Pyrimidone derivatives, preparation method thereof and application thereof in resisting mycobacterium tuberculosis infection 中国医学科学院医药生物技术研究所 2020-11-13 CN claimed
EP-3074044-A2 SYNAPTOJANIN-2 INHIBITORS AND USES THEREOF Yeda Research and Development Co., Ltd. (IL) 2016-10-05 EP claimed
WO-2015079413-A2 SYNAPTOJANIN-2 INHIBITORS AND USES THEREOF YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2015-06-04 WO claimed
CN-118344381-A Process for preparing 1, 3-benzodioxole heterocyclic compounds 联合疗法公司 2024-07-16 CN disclosed
CN-110741005-B Process for preparing 1, 3-benzodioxole heterocyclic compounds 联合疗法公司 2024-04-12 CN disclosed
US-20230303561-A1 PYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREOF AND USE THEREOF IN RESISTING MYCOBACTERIUM TUBERCULOSIS INFECTION INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2023-09-28 US disclosed
CN-114081890-B Application of pyrimidinone derivative in resisting tubercle bacillus infection 中国医学科学院医药生物技术研究所 2023-06-02 CN disclosed
EP-4180429-A1 PYRIMIDINONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF AGAINST MYCOBACTERIUM TUBERCULOSIS INFECTION Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences (CN) 2023-05-17 EP disclosed
CN-114085234-A Process for preparing 1, 3-benzodioxole heterocycles 联合疗法公司 2022-02-25 CN disclosed
EP-0980867-A1 KETONE DERIVATIVES AND MEDICINAL USE THEREOF TORAY INDUSTRIES, INC. (JP) 2000-02-23 EP disclosed
EP-0962456-A1 CYCLIC KETONE DERIVATIVE AND PHARMACEUTICAL USE THEREOF TORAY INDUSTRIES, INC. (JP) 1999-12-08 EP disclosed
EP-0841063-A1 KETONE DERIVATIVES AND MEDICINAL USE THEREOF TORAY INDUSTRIES, INC. (JP) 1998-05-13 EP disclosed
EP-0324431-B1 NEW INDOLYLPIPERIDINE COMPOUNDS, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1992-03-25 EP disclosed
US-5017703-A Antiallergens, antiinflammatory FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) 1991-05-21 US disclosed
US-4935432-A ANTIALLERGENS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1990-06-19 US disclosed
EP-0324431-A1 New indolylpiperidine compounds, processes for the preparation thereof and pharmaceutical composition comprising the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1989-07-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303561-A1 PYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREOF AND USE THEREOF IN RESISTING MYCOBACTERIUM TUBERCULOSIS INFECTION DHPS, DHFR, QDPR MAPT 3364/4885KDM4E 1814/4885MAPK1 954/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.